Science

Alpha Tau signed an agreement with Nasdaq-listed SPAC Healthcare Capital Corp to continue delivering on its radiation cancer treatment.

The BriLife vaccine will be tested in Phase II and III trials in Georgia, Ukraine, and Israel as part of a deal with NRx Pharmaceuticals.

The investment now brings Aidoc’s total funding to $140 million to support a surge in demand for its AI-driven solutions.

The agreement is the "first step on the way to a groundbreaking strategic collaboration in the food tech industry in Israel."

Israeli cultivated meat startup Aleph Farms says it plans to use the funds to advance large-scale global commercialization and expand into new types of animal protein.

OncoHost's platform combines proteomic analysis with AI to predict host responses to immunotherapy, and gain insight into cancer treatments.

The investment is part of the EIC strategy to identity and support high-impact startups and small companies.

Clair Labs has developed technology to track a patient’s health contact-free by monitoring physiological markers, such as heart rate.

Sight Diagnostics will partner with Shaare Zedek Medical Center to detect blood cancer with AI tech and patient information.

Recent findings from the Weizmann Institute show how personalized nutrition in relation to gut health paves the way for medical advances.

ZzappMalaria developed a mobile app and dashboard that helps eliminate malaria, a disease that affects nearly half of the world’s population.

Founded in 2017, Better Juice developed a unique enzymatic technology that reduces the caloric and sugar content in fruit juice while increasing the amount of fiber.

An Israeli study says that while medical cannabis is effective for some symptoms, it can also have a number of negative side effects.

Kahr said the funding will be used to advance clinical development for DSP107, the fusion protein meant to treat blood and bone cancers.

MigVax is ready to begin human clinical trials with its oral vaccine and is on track to market it as a booster in the next year.